- Home
- PDO vs NRIX Comparison
PDO vs NRIX Comparison
Compare PDO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDO
- NRIX
- Stock Information
- Founded
- PDO 2020
- NRIX 2009
- Country
- PDO United States
- NRIX United States
- Employees
- PDO N/A
- NRIX N/A
- Industry
- PDO Trusts Except Educational Religious and Charitable
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- PDO Finance
- NRIX Health Care
- Exchange
- PDO Nasdaq
- NRIX Nasdaq
- Market Cap
- PDO 1.6B
- NRIX 1.4B
- IPO Year
- PDO N/A
- NRIX 2020
- Fundamental
- Price
- PDO $13.55
- NRIX $19.14
- Analyst Decision
- PDO
- NRIX Strong Buy
- Analyst Count
- PDO 0
- NRIX 17
- Target Price
- PDO N/A
- NRIX $30.29
- AVG Volume (30 Days)
- PDO 520.0K
- NRIX 832.5K
- Earning Date
- PDO 01-01-0001
- NRIX 02-13-2025
- Dividend Yield
- PDO 11.80%
- NRIX N/A
- EPS Growth
- PDO N/A
- NRIX N/A
- EPS
- PDO N/A
- NRIX N/A
- Revenue
- PDO N/A
- NRIX $56,424,000.00
- Revenue This Year
- PDO N/A
- NRIX N/A
- Revenue Next Year
- PDO N/A
- NRIX $3.79
- P/E Ratio
- PDO N/A
- NRIX N/A
- Revenue Growth
- PDO N/A
- NRIX N/A
- 52 Week Low
- PDO $10.65
- NRIX $7.65
- 52 Week High
- PDO $13.31
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- PDO 50.91
- NRIX 45.09
- Support Level
- PDO $13.37
- NRIX $17.50
- Resistance Level
- PDO $13.83
- NRIX $20.50
- Average True Range (ATR)
- PDO 0.15
- NRIX 1.12
- MACD
- PDO -0.00
- NRIX 0.16
- Stochastic Oscillator
- PDO 54.41
- NRIX 54.67
About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.